Literature DB >> 17110271

Neuroprotection in Parkinson's disease: and now for something completely different?

Anthony E Lang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17110271     DOI： 10.1016/S1474-4422(06)70605-6

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN： 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  6 in total

1.  Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future.

Authors:  Anthony E Lang
Journal:  Nat Med       Date:  2010-09-21       Impact factor: 53.440

2.  Detoxified extract of Rhus verniciflua stokes inhibits rotenone-induced apoptosis in human dopaminergic cells, SH-SY5Y.

Authors:  Kumar Sapkota; Seung Kim; Se-Eun Park; Sung-Jun Kim
Journal:  Cell Mol Neurobiol       Date:  2011-03       Impact factor: 5.046

3.  A highly reproducible rotenone model of Parkinson's disease.

Authors:  Jason R Cannon; Victor Tapias; Hye Mee Na; Anthony S Honick; Robert E Drolet; J Timothy Greenamyre
Journal:  Neurobiol Dis       Date:  2009-05       Impact factor: 5.996

4.  Launching invasive, first-in-human trials against Parkinson's disease: ethical considerations.

Authors:  Jonathan Kimmelman; Alex John London; Bernard Ravina; Tim Ramsay; Mark Bernstein; Alan Fine; Frank W Stahnisch; Marina Elena Emborg
Journal:  Mov Disord       Date:  2009-10-15       Impact factor: 10.338

5.  Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson's disease.

Authors:  Lars Tönges; Tobias Frank; Lars Tatenhorst; Kim A Saal; Jan C Koch; Éva M Szego; Mathias Bähr; Jochen H Weishaupt; Paul Lingor
Journal:  Brain       Date:  2012-10-19       Impact factor: 13.501

6.  Mitochondrial function and morphology are impaired in parkin-mutant fibroblasts.

Authors:  Heather Mortiboys; Kelly Jean Thomas; Werner J H Koopman; Stefanie Klaffke; Patrick Abou-Sleiman; Simon Olpin; Nicholas W Wood; Peter H G M Willems; Jan A M Smeitink; Mark R Cookson; Oliver Bandmann
Journal:  Ann Neurol       Date:  2008-11       Impact factor: 10.422
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.